Asia Pacific Uterine Cancer Market Size & Outlook, 2025-2033


Asia Pacific Uterine Cancer Market Insights

  • Reed Intelligence analysis indicates that the Asia Pacific Uterine Cancer Market size, which was USD 1033.53 Million in 2024, is projected to attain USD 1584.38 Million by 2033.
  • The market is expected to register a CAGR of 4.95% over the period 2026–2033.
  • In 2024, Endometrial Adenocarcinoma emerged as the dominant By Type based on market size.
  • Papillary Serous Carcinoma is projected to register the fastest growth, positioning it as the most attractive By Type segment over the forecast horizon.

Other Key Findings


  • Asia Pacific represented 16.51% of the global Uterine Cancer Market size in 2024.
  • By 2033, United States is estimated to hold the largest position in the global market in terms of size.
  • South Korea is estimated to remain the fastest-growing market in Asia Pacific, advancing to USD 82.51 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 1033.53 Million
Market Size In 2033 USD 1584.38 Million
Largest segment Endometrial Adenocarcinoma
Units Revenue in USD Million
CAGR 4.95% (2025-2033)
Segmnetation Covered
Asia Pacific
  1. China
  2. India
  3. Japan
  4. Korea
  5. Taiwan
  6. Australia
  7. Singapore
  8. South East Asia
By Type
  1. Endometrial Adenocarcinoma
  2. Adenosquamous Carcinoma
  3. Papillary Serous Carcinoma
  4. Uterine Sarcoma
By Treatment
  1. Diagnosis
  2. Therapeutic Treatment
  3. Surgery
By End-Users
  1. Hospitals
  2. Diagnostic Centers
  3. Drug Stores
  4. Online Pharmacies
  5. Other End Users
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends